LIXTE Biotechnology Holdings (NASDAQ: LIXT) announced the filing of its first-quarter 2026 Form 10-Q, highlighting continued advancement of its lead oncology candidate, LB-100, including expansion of its ovarian cancer trial following favorable safety findings in combination with immunotherapy. The company also cited continued growth at its recently acquired Liora Technologies Europe subsidiary as it pursues broader strategic expansion to strengthen its oncology pipeline and treatment development capabilities.
LB-100 is a first-in-class PP2A inhibitor that has demonstrated tolerability in cancer patients at doses associated with anti-cancer activity. Based on published preclinical data, LB-100 has the potential to significantly enhance chemotherapies and immunotherapies and improve outcomes for patients with cancer. The compound is part of a pioneering effort in an entirely new field of cancer biology – activation lethality – that is advancing a new treatment paradigm. LIXTE’s novel approach is covered by a comprehensive patent portfolio, with proof-of-concept clinical trials currently in progress for Ovarian Clear Cell Carcinoma, Metastatic Colon Cancer and Advanced Soft Tissue Sarcoma.
Through its wholly owned subsidiary, Liora Technologies Europe Ltd., LIXTE is also pioneering the development of electronically controlled proton therapy systems for treating tumors in various types of cancers. Liora’s proprietary flagship technology, the LiGHT System, is believed to provide significant advantages over currently available technologies for treating tumors with proton therapy. The expansion of Liora Technologies underscores LIXTE’s commitment to broadening its capabilities in cancer treatment development.
The strategic expansion reflects the company's dual focus on both pharmacological and technological innovations in oncology. By advancing LB-100 in clinical trials and integrating Liora's proton therapy technology, LIXTE aims to address multiple facets of cancer treatment. The company's progress in the first quarter of 2026 demonstrates its dedication to moving its pipeline forward while strengthening its operational base.
For more details on the press release, visit https://ibn.fm/oHzhK. Additional information about LIXTE and its pipeline can be found at www.lixte.com, and more about Liora Technologies is available at www.lioratechnologies.com.
